- Myriad Genetics press release (NASDAQ:MYGN): Q4 Non-GAAP EPS of -$0.12 beats by $0.05.
- Revenue of $177.8M (+10.6% Y/Y) beats by $8.38M.
- Fourth quarter testing volumes grew 26% year-over-year, and 11% year-over-year excluding the contribution from the recent acquisition of Gateway Genomics and its SneakPeek Early Gender DNA Test.
- GeneSight, the company's pharmacogenomics test, grew revenue 36% for the full year 2022.
- FY23 Guidance: Revenue of $720M-$750M vs consensus of $725.43M; Adj EPS loss of $(0.40)-$(0.20) vs consensus of -$0.30
- 1Q23 Guidance: Revenue of $170M-$172M vs consensus of $725.43M; Adj EPS loss of $(0.20)-$(0.18).